AI Article Synopsis

  • * A meta-analysis reviewed 232 studies, narrowing down to 39 randomized controlled trials (RCTs) with 1924 patients, assessing the effectiveness and patient adherence of both the 1000 mg and 500 mg dosages.
  • * Results showed no significant differences in patient compliance, efficacy, adverse events, or quality of life scores between the two dosages, suggesting the higher dose is just as effective as the standard regimen for chronic venous disease patients.

Article Abstract

Background: Micronized purified flavonoid fraction (MPFF) is a widely prescribed and extensively investigated venoactive drug (VAD). The standard dosage for MPFF is 500 mg administered twice daily. However, a new daily dose of 1000 mg has just been introduced.

Objective: This study investigated whether a daily dose of 1000 mg MPFF could be implemented and embraced by the public and still has the same therapeutic effects as conventional pharmaceuticals.

Methods: For this meta-analysis, we searched MEDLINE, Embase, Science of Web, Cochrane, and PubMed databases and forward and backward citations for studies published between database inception and March 2023. Three randomized controlled trials (RCTs) of comparison of different dosages of MPFF to evaluate whether there is a significant difference between them were included, without language or date restrictions. Due to the small sample size of the study included, we conducted a simple sensitivity test using a one-by-one exclusion method, and the results showed that the study did not affect the final consolidation conclusion. The quality of the evidence was assessed using the Cochrane risk-of-bias tool.

Results: Out of 232 studies, 99 were eligible and 39 RCTs had data, all with low to moderate bias. Overall, 1924 patients (experimental group: 967, control group: 957) in 3 RCTs met the criteria. There is no significant difference in patient compliance, efficacy, clinical adverse events, and quality of life scores between MPFF 1000 mg once daily and MPFF 500 mg twice daily (standardized mean difference [SMD]: 0.049 [0.048, 0.145], p=0.321, risk ratio [RR]: 0.981 [0.855, 1.125], p=0.904, and SMD: 0.063 [0.034, 0.160], p=0.203).

Interpretation: In symptomatic chronic venous disease patients, MPFF 1000 mg once daily and MPFF 500 mg twice daily improve patient compliance, lower limb discomfort, clinical adverse events, and quality of life scores similarly. Regular medical care should recommend MPFF 1000 mg daily more often.

Clinical Impact: Micronized purified flavonoid fraction (MPFF) is a popular venoactive medication (VAD) in modern medicine.MPFF is effective in treating lower extremity venous problems.Currently, besides conventional 500 mg tablets, there exist alternative dosage forms such as solutions, chewable tablets, and other novel formulations for MPFF.The excessive frequency and amount of medication may have a negative impact on patient adherence.

Download full-text PDF

Source
http://dx.doi.org/10.1177/15266028241262700DOI Listing

Publication Analysis

Top Keywords

micronized purified
12
purified flavonoid
12
mpff 500
12
mpff 1000
12
1000 daily
12
mpff
10
lower limb
8
chronic venous
8
venous disease
8
flavonoid fraction
8

Similar Publications

Introduction: Mesenchymal stem cells (MSCs) have promising regenerative properties in tissue repair and anti-inflammatory responses. This study aimed to investigate the effects of MSCs and their combination with micronized purified flavonoid fraction (MPFF) in a croton oil-induced hemorrhoids model on tissue edema, inflammation, and underlying molecular mechanisms.

Material And Methods: MSCs were isolated and characterized for their adherence, differentiation capacity, and immunophenotyping.

View Article and Find Full Text PDF

Background: Hemorrhoidal disease (HD) significantly impacts patients' quality of life. This study aimed to evaluate the effectiveness of preoperative treatment with the micronized purified flavonoid fraction (MPFF) and a sucralfate-based rectal ointment in managing HD symptoms and reducing interventions.

Methods: A prospective quasi-experimental study including consecutive cases and controls matched on the basis of sex was performed in a tertiary referral center.

View Article and Find Full Text PDF

Objective: Evaluation of the effectiveness of flavonoids in the postoperative management of patients with hemorrhoids.

Material And Methods: A single-center randomized controlled clinical trial was conducted. Patients with stage III and IV hemorrhoids aged over 18 years who patients who underwent hemorrhoidectomy were included.

View Article and Find Full Text PDF

Chronic Venous Insufficiency Evaluation and Medical Management.

Curr Cardiol Rep

November 2024

Department of Medicine, University of North Carolina, Rex Vascular Specialists UNC Health, 4414 Lake Boone Trail, Suite 505, Chapel Hill, NC, 27607, USA.

Article Synopsis
  • This review focuses on evaluating chronic venous insufficiency (CVI), improving diagnostic methods, and advancing treatments to enhance patient outcomes.
  • CVI is often overlooked but can significantly affect patients; evaluation includes personal and family history of related conditions, with duplex ultrasound as the primary diagnostic tool.
  • Treatment mainly involves compression therapy, with growing interest in lifestyle changes and micronized purified flavanoid fraction (MPFF) to relieve symptoms and boost quality of life.
View Article and Find Full Text PDF

The efficacy of Aescin combined with MPFF for early control of bleeding from acute hemorrhoids, A randomized controlled trial.

Asian J Surg

August 2024

Division of Colorectal Surgery, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Clinical Surgical Research Center, Chiang Mai University, Chiang Mai, Thailand.

Background: Hemorrhoidal disease, affecting over 20 % of the population, presents management challenges due to its multifaceted nature. While treatments like Micronized Purified Flavonoid Fraction (MPFF) show promise, Aescin's efficacy remains uncertain. This study assesses the combined effectiveness of Aescin with MPFF against MPFF alone in treating Grades 1 and 2 hemorrhoids, focusing on halting bleeding and reducing mass effect.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!